GYRE (Gyre Therapeutics) Other Gross PPE : $2.0 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gyre Therapeutics Other Gross PPE?

Gyre Therapeutics's Other Gross PPE for the quarter that ended in Sep. 2024 was $2.0 Mil.

Gyre Therapeutics's quarterly Other Gross PPE increased from Mar. 2024 ($0.4 Mil) to Jun. 2024 ($2.1 Mil) but then declined from Jun. 2024 ($2.1 Mil) to Sep. 2024 ($2.0 Mil).

Gyre Therapeutics's annual Other Gross PPE increased from Dec. 2021 ($0.4 Mil) to Dec. 2022 ($1.0 Mil) but then declined from Dec. 2022 ($1.0 Mil) to Dec. 2023 ($0.5 Mil).

Gyre Therapeutics Other Gross PPE Historical Data

The historical data trend for Gyre Therapeutics's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gyre Therapeutics Other Gross PPE Chart

Gyre Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Other Gross PPE

0.35

1.00

0.49

Gyre Therapeutics Quarterly Data
	Dec21	Mar22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Gross PPE	Get a 7-Day Free Trial					-	0.49	0.36	2.10	1.98

Gyre Therapeutics Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Gyre Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gyre Therapeutics Inc (NAS:GYRE) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

L9S:Germany

Address

12770 High Bluff Drive, Suite 150, San Diego, CA, USA, 92130

Website

https://www.gyretx.com

Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.